Biocon Biologics and Civica Inc Collaborate to Enhance Diabetes Care in the US

Enhancing Diabetes Care Through Collaborative Innovation

New Delhi, Mar 6 (PTI) - Biocon Biologics has announced a pivotal collaboration with Civica Inc, a not-for-profit generic pharmaceutical organization, to expand access and affordability of Insulin Aspart in the US. This strategic partnership allows Biocon Biologics to provide the drug substance necessary for the production of this rapid-acting insulin analog.

Collaboration Details and Objectives

• Biocon Biologics will supply Insulin Aspart drug substance to Civica Inc.
• Civica will utilize its Petersburg, Virginia facility to manufacture the insulin product.
• The aim is to enhance affordability and access to insulin for diabetes patients in the US.

Following completion of the development work and clinical trials, Civica will commercialize the insulin product. This partnership underscores Biocon's commitment to creating lasting value in diabetes care, as expressed by Shreehas Tambe, CEO of Biocon Biologics.

Addressing Diabetes in America

• Approximately 38.4 million Americans are living with diabetes.
• About 11.6% of the U.S. population is impacted by this condition.
• Nearly a quarter of those affected remain undiagnosed.
• Additionally, over 97 million are classified as prediabetic.

Ned McCoy, CEO of Civica, emphasized the importance of this collaboration in fulfilling their mission to improve diabetes management in the United States. The partnership not only enhances access to Insulin Aspart but also progresses Biocon Biologics' own product currently under review by the FDA.